Antigen fused with porcine Fc fragment and vaccine composition comprising the same

Abstract

Provided is an antigen fused with a porcine Fc fragment, a vaccine composition having a self-adjuvanting effect by binding an Fc fragment to various antigens, and a method of producing the antigen.

Claims

1. A vaccine composition comprising, as an active ingredient, an antigen fused with a porcine Fc fragment consisting of the amino acid sequence of SEQ ID NO: 4.

2. The vaccine composition of claim 1, wherein the antigen has a self-adjuvanting effect and increased solubility through fusion with the Fc fragment.

3. An expression vector of a recombinant antigen having a self-adjuvanting effect, the expression vector comprising a polynucleotide encoding a porcine Fc fragment consisting of the amino acid sequence of SEQ ID NO: 4 and a polynucleotide encoding an antigen.

4. The expression vector of claim 3 further comprising a promotor gene, wherein the promoter gene, the polynucleotide encoding the porcine Fc fragment, and the polynucleotide encoding the antigen are sequentially linked.

5. The expression vector of claim 4, wherein the promoter comprises one or more selected from the group consisting of a 35S promoter derived from cauliflower mosaic virus, a 19S RNA promoter derived from cauliflower mosaic virus, an actin protein promoter of a plant, an ubiquitin protein promoter, a cytomegalovirus (CMV) promoter, a simian virus 40 (SV40) promoter, a respiratory syncytial virus (RSV) promoter, a pEMU promoter, an MAS promoter, a histone promoter, a Clp promoter, and an elongation factor-1 alpha (EF-1) promoter.

6. The expression vector of claim 3 further comprising comprises a polynucleotide encoding a chaperone binding protein (BiP).

7. The expression vector of claim 3 further comprising comprises a gene encoding a His-Asp-Glu-Leu (HDEL) (SEQ ID NO: 20) peptide.

8. The expression vector of claim 3 further comprising comprises a 5 untranslated region (UTR) site gene of M17.

9. The expression vector of claim 3, wherein the expression vector increases an expression amount and solubility of the Fc fragment-fused antigen.

10. A method of producing a recombinant antigen having a self-adjuvanting effect, the method comprising: (a) culturing transgenic cells transformed with the expression vector of claim 3; and (b) isolating and purifying a porcine Fc fragment-fused antigen from the transgenic cells or a culture broth thereof.

11. A method of preventing or treating an infectious disease, the method comprising administering, to a subject in need thereof, the composition of claim 1.

Description

DESCRIPTION OF DRAWINGS

(1) FIG. 1 is a view illustrating a pCAMBIA1300 vector map according to an embodiment of the present invention.

(2) FIG. 2 is a view illustrating arrangement of genes for expressing a pFc-fused VP1 recombinant protein according to an embodiment of the present invention.

(3) FIG. 3 illustrates western blotting results of confirming an expression amount of a pFc-fused VP1 recombinant protein according to an embodiment of the present invention.

(4) FIG. 4 illustrates western blotting results of confirming the stability of a pFc-fused VP1 recombinant protein according to an embodiment of the present invention.

(5) FIG. 5 illustrates western blotting results of confirming the solubility of a pFc-fused VP1 recombinant protein according to an embodiment of the present invention.

(6) FIG. 6 illustrates western blotting results of confirming the solubility of pFc-fused GP5 recombinant antigen according to an embodiment of the present invention.

(7) FIG. 7 illustrates western blotting results of confirming the solubility and productivity of a pFc-fused PCV2 recombinant protein according to an embodiment of the present invention.

(8) FIG. 8 illustrates results of confirming the productivity of a pFc-fused E2 recombinant antigen according to an embodiment of the present invention.

(9) FIG. 9 illustrates results of confirming the immunogenicity of a pFc-fused E2 recombinant antigen according to an embodiment of the present invention, wherein the antigen was administered once.

(10) FIG. 10 illustrates results of confirming the immunogenicity of a pFc-fused E2 recombinant antigen according to an embodiment of the present invention, wherein the antigen was administered twice.

BEST MODE

(11) In the present invention, it has been confirmed that, when various antigens are bound to a porcine Fc fragment, not only an expression amount and productivity but also solubility and stability of an antigen are increased by the fragment, and it is an object of the present invention is to provide an antigen fused with the porcine Fc fragment, an expression vector including a polynucleotide encoding the porcine Fc fragment and a polynucleotide encoding an antigen, and a method of producing a recombinant antigen using the expression vector.

(12) As used herein, the term Fc fragment refers to an Fc fragment not having an antigen binding site, in which only a heavy chain (H chain) portion is linked by an SS bond, when an immunoglobulin is digested with papain, and the Fc fragment of the present invention is preferably a porcine Fc fragment, more preferably a porcine Fc fragment represented by SEQ ID NO: 4, but the present invention is not limited thereto, and any Fc fragment that increases the expression amount and solubility of a target antigen when fused with the target antigen may be used. In addition, a variant of the Fc fragment of SEQ ID NO: 4 of the present invention is within the scope of the present invention. Specifically, the gene may include a base sequence having 90% or more, preferably 95% or more, and more preferably 98% or more sequence homology to the base sequence of SEQ ID NO: 3. The % sequence homology with respect to a polynucleotide is determined by comparing optimally-arranged sequences with a comparative region, and a part of the polynucleotide sequence in the comparative region may include an addition or deletion (i.e., a gap) compared to a reference sequence (without an addition or deletion) with respect to the optimal arrangement of the sequences.

(13) As used herein, the term antigen collectively refers to any substance inducing immune responses in vivo, and the antigen is preferably a virus, a compound, a bacterium, pollen, a cancer cell, a shrimp, or a peptide or protein of a part thereof, but is not particularly limited as long as it is a substance capable of inducing an immune response in vivo.

(14) As used herein, the term vaccine refers to a biological agent including an antigen that causes an immune response in vivo and an immunogen that causes the living body to have immunity via injection or oral administration thereof to a human or an animal to prevent infectious diseases. The animal refers to humans or non-human animals, and the non-human animals refer to pigs, cows, horses, dogs, goat, and sheep, but the present invention is not limited thereto.

(15) As used herein, the term target protein refers to a protein to be produced using a genetic engineering method, and the target protein may be preferably commercially available antigens in need of mass production and more preferably, an antigen, an antibody, an antibody fragment, a structural protein, a regulatory protein, a transcription factor, a toxin protein, a hormone, a hormone analogue, a cytokine, an enzyme, an enzyme fragment, an enzyme inhibitor, a transport protein, a receptor, a receptor fragment, a bio-defense inducer, a storage protein, a movement protein, an exploitive protein, or a reporter protein, but the present invention is limited thereto, and any protein capable of being produced with the expression vector of the present invention may be used.

(16) As used herein, the term expression vector refers to a vector capable of expressing a peptide or protein encoded by a heterologous nucleic acid inserted into the vector, and preferably means a vector constructed so as to express a porcine Fc fragment-fused target antigen. The term vector as used herein refers to any vehicle for the introduction and/or transfer of a base into a host cell in vitro, ex vivo, or in vivo, and may mean a replicon to which another DNA fragment may be attached so as to bring about the replication of the attached fragment. The term replicon refers to any genetic unit (e.g., a plasmid, a phage, a cosmid, a chromosome, a virus, and the like) that functions as an autonomous unit of DNA replication in vivo, i.e., is capable of replicating by self-regulation. The expression vector of the present invention may preferably include a promoter which is a transcription initiation factor to which an RNA polymerase binds, an arbitrary operator sequence for regulating transcription, a sequence encoding a suitable mRNA ribosome binding site, a sequence regulating the termination of transcription and translation, a terminator, or the like. More preferably, the expression vector may further include a 5 UTR site gene of M17, a BiP gene for transporting a target protein to a vesicle, an HDEL (SEQ ID NO: 20) gene for minimizing the degradation of a protein so that the protein can be stably maintained in a vesicle, or the like. More preferably, the expression vector may further include a gene for a tag for easily isolating a recombinant protein, a marker gene for selecting an antibiotic-resistant gene or the like to select a transgenic organism, or the like.

(17) The gene for a tag may be additionally included for easy separation, other than the Fc fragment of the present invention, which is a tag protein, and examples thereof may include an Avi tag, a Calmodulin tag, a polyglutamate tag, an E tag, a FLAG tag, a HA tag, a His tag, a Myc tag, an S tag, an SBP tag, an IgG-Fc tag, a CTB tag, a Softag 1 tag, a Softag 3 tag, a Strep tag, a TC tag, a V5 tag, a VSV tag, an Xpress tag, and the like. Examples of the marker gene for selection may include genes resistant to herbicide such as glyphosate and phosphinothricin, genes resistant to antibiotics such as kanamycin, G418, bleomycin, hygromycin, and chloramphenicol, the aadA gene, and the like, examples of the promoter may include a pEMU promoter, an MAS promoter, a histone promoter, a Clp promoter, a 35S promoter derived from cauliflower mosaic virus, a 19S RNA promoter derived from cauliflower mosaic virus, an actin protein promoter of a plant, an ubiquitin protein promoter, a cytomegalovirus (CMV) promoter, a simian virus 40 (SV40) promoter, a respiratory syncytial virus (RSV) promoter, an elongation factor-1 alpha (EF-1) promoter, and the like, and examples of the terminator may include nopaline synthase (NOS), a rice amylase RAmyl A terminator, a phaseolin terminator, an Octopine gene terminator of Agrobacterium tumefaciens, and an E. coli rrnB1/B2 terminator, but these are merely examples and the present invention is not limited thereto.

(18) As used herein, the term fusion antigen refers to a recombinant protein produced by fusion of a porcine Fc fragment and a target antigen, and preferably means a recombinant antigen with enhanced solubility through fusion with the Fc fragment, but the present invention is not limited thereto, and any recombinant antigen produced through binding with a porcine Fc fragment may be used.

(19) As used herein, the term transformation collectively refers to changes in the genetic properties of an organism by injected DNA, and the term transgenic organism refers to a living organism produced by injecting an external gene using a molecular genetic method, and preferably means a living organism transformed by the expression vector of the present invention. The living organism is not particularly limited as long as it is a living organism such as microorganisms, eukaryotic cells, insects, animals, plants, and the like, and examples thereof include, but are not limited to, E. coli, Salmonella, Bacillus, yeast, animal cells, mice, rats, dogs, monkeys, pigs, horses, cows, Agrobacterium tumefaciens, and plants. The transgenic organism may be produced using a method such as transformation, transfection, an Agrobacterium-mediated transformation method, particle gun bombardment, sonication, electroporation, and a polyethylene glycol (PEG)-mediated transformation method, but the present invention is not limited thereto, and any method capable of injecting the vector of the present invention may be used.

(20) As used herein, the term solubility refers to a degree to which a target protein or a peptide can be dissolved in a solvent suitable for administration to the human body. Specifically, the solubility may indicate a degree to which a solute is saturated with respect to a given solvent at a particular temperature. The solubility may be measured by determining the saturation concentration of a solute, for example, by adding an excess amount of a solute to a solvent and stirring and filtering the solution, and then measuring the concentration thereof using a UV spectrometer, HPLC, or the like, but the present invention is not limited thereto. High solubility is more suitable for the isolation and purification of recombinant proteins, and inhibits the agglomeration of recombinant proteins, and thus it is effective in maintaining the physiological activity or pharmacological activity of recombinant proteins.

(21) As used herein, the term prevention means all actions that inhibit or delay the onset of a disease such as an infectious disease, cancer, or the like via administration of the vaccine composition according to the present invention.

(22) As used herein, the term treatment means all actions that improve or beneficially change symptoms of an infectious disease, cancer, or the like via administration of the vaccine composition according to the present invention.

(23) As used herein, the term individual refers to a subject to which the vaccine composition of the present invention may be administrated, and the subject is not particularly limited.

(24) The vaccine composition of the present invention may be formulated into oral preparations such as powder, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, and the like, and sterile injectable solutions. The formulation may be performed using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, or the like. Solid preparations for oral administration include tablets, pills, powder, granules, capsules, and the like, and these solid preparations may be formulated by mixing a lecithin-like emulsifier with at least one excipient, for example, starch, calcium carbonate, sucrose, lactose, gelatin, or the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration may include suspensions, liquids for internal use, emulsions, syrups, and the like, and these liquid preparations may include, in addition to simple commonly used diluents, such as water and liquid paraffin, various types of excipients, for example, a wetting agent, a sweetener, a flavoring agent, a preservative, and the like. Preparations for parenteral administration include an aqueous sterile solution, a non-aqueous solvent, a suspension, an emulsion, and a freeze-dried preparation. Non-limiting examples of the non-aqueous solvent and the suspension include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and an injectable ester such as ethyl oleate. In addition, the vaccine composition may further include a known adjuvant. Although any adjuvant known in the art may be used as the adjuvant without limitation, the vaccine composition may further include, for example, Freund complete adjuvant or incomplete adjuvant to increase the immunogenicity thereof.

(25) The vaccine composition of the present invention may be formulated in the form of oral preparations such as powder, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, and the like, preparations for external application, suppositories, and sterile injection solutions, according to general methods.

(26) Administration routes of the vaccine composition according to the present disclosure include, but are not limited to, oral administration, intravenous administration, intramuscular administration, intra-arterial administration, intramedullary administration, intradural administration, intracardiac administration, transdermal administration, subcutaneous administration, intraperitoneal administration, intranasal administration, intestinal administration, topical administration, sublingual administration, and rectal administration. The vaccine composition may be administered orally or parenterally. The term parenteral as used herein is intended to include subcutaneous, intradermal, intravenous, intramuscular, intra-articular, intrabursal, intrasternal, intradural, intralesional, and intracranial injections or injection techniques. The vaccine composition of the present invention may also be administered in the form of a suppository for rectal administration.

(27) A dose of the vaccine composition according to the present invention is selected in consideration of the age, body weight, gender, physical condition, and the like of an individual. An amount required to induce an immunoprotective response in an individual without any side effects may vary depending on the presence of recombinant proteins as immunogens and excipients. Generally, each dose includes the recombinant protein of the present invention in an amount of 0.1 g to 1,000 g, preferably 0.1 g to 100 g, with respect to 1 ml of a sterile solution thereof. If needed, arbitrarily repeated antigen stimulation may be performed after an initial dose of the vaccine composition.

(28) As used herein, the term adjuvant generally refers to any substance that increases humoral and/or cellular immune responses against an antigen, and the term self-adjuvanting response means a response in which a recombinant antigen itself increases humoral and/or cellular immune responses against an antigen, as compared to existing antigens, and preferably means increasing immunogenicity of an antigen by binding the antigen to a porcine Fc fragment.

(29) Hereinafter, exemplary embodiments will be described to aid in understanding the present invention. However, the following examples are provided only to facilitate the understanding of the present invention and are not intended to limit the scope of the present invention.

EXAMPLES

Example 1: Preparation of pFc-Fused VP1 Recombinant Protein Expression Vector

(30) To prepare an expression vector for producing a recombinant protein with increased separation and purification efficiency through an increase in expression amount of a target protein and enhancement of the solubility thereof, pFc1 (SEQ ID NO: 1), pFc2 (SEQ ID NO: 3), or pFc3 (SEQ ID NO: 5) of a porcine Fc fragment (pFc) was used to construct an expression vector. More specifically, as illustrated in FIGS. 1 and 2, a 5 untranslated region (UTR) site gene (SEQ ID NO: 7) of M17, a polynucleotide (SEQ ID NO: 8) encoding a chaperone binding protein (BiP), a VP1 gene (SEQ ID NO: 9) of the foot-and-mouth disease virus (FMDV), a polynucleotide encoding a pFc, and a polynucleotide encoding a His-Asp-Glu-Leu (HDEL) (SEQ ID NO: 20) protein were sequentially cloned into between a CaMV 35S promoter gene and an NOS terminator of a pCAMBIA1300 vector, thereby completing the preparation of an expression vector. For the pFc fragment, different expression vectors were prepared by inserting pFc1, pFc2, or pFc3.

Example 2: Experiment for pFc-Fused VP1 Recombinant Protein Expression

(31) 2.1. Experiment for Confirming Expression Amount of pFc-Fused VP1 Recombinant Protein

(32) To identify protein expression amounts of a pFc-fused VP1 recombinant protein expression vector prepared in the same manner as in Example 1, the vector was introduced into a protoplast isolated from Arabidopsis leaves by PEG-mediated transformation to prepare a transgenic organism, and then the cultured protoplast was collected and lysed, and an expression pattern of BiP:FMDV-VP1:pFc, which is a recombinant protein expressed therefrom, was confirmed by western blotting using a pFc-recognizing anti-pig secondary antibody (1:5,000, Abcam). More specifically, 30 L of a cell lysate was mixed with an SDS sample buffer and then heated. Then, proteins were separated on a 10% SDS-PAGE gel according to size by electrophoresis, the separated proteins were transferred to a PVDF membrane, followed by blocking using 5% skim milk, and then the proteins were subjected to binding to antibodies and treated with an ECL solution using a method provided by a manufacturer to identify pFc-fused recombinant proteins. The results thereof are illustrated in FIG. 3.

(33) As illustrated in FIG. 3, it was confirmed that the expression amount of the pFc2-fused recombinant protein was highest among the recombinant proteins fused with various pFc fragments. From the above results, it was confirmed that the same immunoglobulin fragments did not exhibit the same effect.

(34) 2.2. Stability Confirmation Experiment for pFc-Fused VP1 Recombinant Protein

(35) To confirm the stability of proteins of a pFc-fused recombinant protein expression vector prepared in the same manner as in Example 1, a sample (0) at the time of extracting the recombinant proteins and a sample (1) obtained after storage at 4 C. for 1 hour were examined by western blotting using the same method as that used in Example 2.1. The results thereof are illustrated in FIG. 4.

(36) As illustrated in FIG. 4, it was confirmed that the pFc2-fused recombinant protein exhibited the greatest expression amount and high stability.

(37) 2.3. Solubility Confirmation Experiment for pFc2-Fused VP1 Recombinant Protein

(38) To confirm the solubility of proteins of a pFc2-fused recombinant protein expression vector prepared in the same manner as in Example 1, leaves of Nicotiana benthamiana were inoculated with Agrobacterium tumefaciens transformed with the vector to express the pFc2-fused recombinant protein (BiP:FMDV-VP1:pFc2) using a transient expression method, proteins were extracted from the plant leaves and centrifuged, and then proteins in a soluble form (S) included in a solution and proteins present in a pellet portion (P) were subjected to western blotting using the same method as that used in Example 2.1. As a control, recombinant proteins produced through fusion of a polynucleotide (SEQ ID NO: 13) encoding a known cellulose binding module (CBM3) instead of the pFc fragment was used. The results thereof are illustrated in FIG. 5.

(39) As illustrated in FIG. 5, it was confirmed that the pFc2-fused recombinant protein was not observed in the pellet portion, while being included in the solution. However, in the case of the CBM3-fused recombinant proteins, a considerable number of recombinant proteins were observed in the pellet portion. From the above results, it was confirmed that the pFc2-fused recombinant protein exhibited increased solubility through structural modification due to binding between a target protein and a pFc2 fragment, from which it was confirmed that the pFc2-fused recombinant protein was more effective in isolation and purification, and was effective in maintaining physiological activity or pharmacological activity due to inhibition of the agglomeration of the recombinant protein.

Example 3: Solubility Confirmation Experiment for pFc2-Fused GP5 Recombinant Antigen

(40) To fuse the pFc2 fragment with a GP5 antigen protein of porcine reproductive and respiratory syndrome (PRRS), a polynucleotide (SEQ ID NO: 11) encoding the porcine GP5 antigen protein was inserted instead of the VP1 gene of FMDV included in the expression vector of Example 1 to prepare an expression vector expressing a GP5:pFc2 recombinant antigen. Then, leaves of Nicotiana benthamiana were inoculated with Agrobacterium tumefaciens transformed with the vector to express the pFc2-fused GP5 recombinant antigen (GP5:pFc2) using a transient expression method, proteins were extracted from the plant leaves and centrifuged, and then proteins in a soluble form (S) included in a solution and proteins present in a pellet portion (P) were subjected to western blotting using the same method as that used in Example 2.1. As a control, a GP5 recombinant antigen fused with CBM3 (SEQ ID NO: 14) instead of the pFc fragment was used, and in the case of the CBM3-fused GP5 recombinant antigen, an experiment was carried out using an HA antibody for western blotting. The results thereof are illustrated in FIG. 6.

(41) As illustrated in FIG. 6, it was confirmed that in the case of the pFc2-fused GP5 recombinant antigen, while some proteins were observed in the pellet portion, most proteins were included in the solution. In contrast, in the case of the CBM3-fused GP5 recombinant antigen, a considerable number of recombinant proteins were observed in the pellet portion. From the above results, it was confirmed that the pFc2-fused recombinant protein exhibited increased solubility regardless of the type of protein.

(42) From these results, it was confirmed that by fusing a porcine Fc fragment, especially a pFc2 fragment including an amino acid sequence represented by SEQ ID NO: 4 with a target protein, the expression amount and solubility of the target protein were increased, and thus the target protein could be stably and easily separated and stored.

Example 4: Productivity and Solubility Confirmation Experiment for pFc2-Fused PCV2 Recombinant Protein

(43) To fuse the pFc2 fragment with a porcine circovirus type 2 (PCV2) protein, a polynucleotide (SEQ ID NO: 15) encoding the PCV2 protein was inserted instead of the VP1 gene of FMDV included in the expression vector of Example 1 to prepare an expression vector expressing a PCV2:pFc2 recombinant protein. Then, leaves of Nicotiana benthamiana were inoculated with Agrobacterium tumefaciens transformed with the vector to express the pFc2-fused PCV2 recombinant protein using a transient expression method, proteins were extracted from the plant leaves and centrifuged, and then proteins in a soluble form (S) included in a solution and proteins present in a pellet portion (P) were subjected to western blotting using the same method as that used in Example 2.1. As a control, a PCV2 recombinant protein fused with His-tag instead of the pFc fragment was used, and in the case of the His-tag-fused PCV2 recombinant protein, an experiment was carried out using an anti-His antibody for western blotting. The results thereof are illustrated in FIG. 7.

(44) As illustrated in FIG. 7, it was confirmed that the pFc2-fused PCV2 recombinant protein was mostly included in the solution and exhibited significantly increased productivity as compared to that of the His-tag-fused PCV2 recombinant protein.

Example 5: Experiment for pFc2-Fused E2 Recombinant Protein Expression

(45) 5.1. Isolation of pFc2-Fused Antigen Protein

(46) To confirm whether the pFc2 fragment is fused to an antigen protein and usable, a polynucleotide (SEQ ID NO: 17) encoding an E2 protein, which is a swine fever antigen, was inserted instead of the VP1 gene of FMDV included in the expression vector of Example 1 to prepare an expression vector expressing a BiP:E2:pFc2 recombinant protein. Then, Arabidopsis thaliana was transformed with the prepared expression vector by an Agrobacterium-mediated transformation method, Arabidopsis thaliana with resistance to kanamycin was selected, and homo-seeds in which the pFc2-fused E2 recombinant protein was stably expressed through generation advancement were finally obtained, thereby completing the preparation of a transformed plant. Then, proteins were isolated from 8 g of the finally obtained transformed plant by using a protein extraction buffer commonly used in protein extraction, and the pFc-fused E2 recombinant protein was isolated using AKTA prime (GE Healthcare) equipped with a Protein A-Sepharose column. Then, as a control, a BiP:E2:CBD recombinant protein produced by fusion of a CBD (SEQ ID NO: 19) instead of the pFc fragment was used. The CBD-fused E2 recombinant protein was isolated from 5 g of the transformed plant using amorphous cellulose (AMC). Thereafter, the isolated recombinant protein was dialyzed with phosphate buffered saline (PBS), and then concentrated using a centrifugal filter tube. To measure the amount of the isolated recombinant protein, the protein was subjected to SDS-PAGE and then Coomassie Blue staining. At this time, the recombinant protein was quantified using a standard curve using bovine serum albumin (BSA). The results thereof are illustrated in FIG. 8.

(47) As illustrated in FIG. 8, it was confirmed that while the CBD-fused E2 recombinant antigen was produced in an amount of about 30 g per 1 g of the plant, the pFc2-fused E2 recombinant antigen was produced in an amount of 302 g per 1 g of the plant. From the above results, it was confirmed that an expression amount of a target antigen could be increased 10-fold or more using the pFc2 fragment.

(48) 5.2. Immunogenicity and Virus Neutralization Ability Confirmation Experiment for pFc2-Fused E2 Recombinant Antigen

(49) To confirm whether the pFc2-fused E2 recombinant antigen has immunogenicity and virus neutralization ability by inducing an antibody in vivo, experiments were carried out using 6-week-old male C57BL/6J mice. More specifically, experimental group mice were administered 1 g of the pFc2-fused E2 recombinant antigen once (6-week-old) or twice (6-week-old and 8-week-old), and negative control mice were administered phosphate-buffered solution. In addition, as a positive control, mice were administered the CBD-fused E2 recombinant antigen at the same dose and the same time as those used in the experimental group. Upon administration of each antigen, each antigen was mixed with the same amount of Freund's adjuvant and administered, and a complete adjuvant was administered in the once-administered group and, in the twice-administered group, an incomplete adjuvant was administered after administration of a complete adjuvant. Then, blood was collected at the time when the experiment was started and every week from 1 week after administration of each antigen, and it was examined using an antibody kit for clinical diagnosis for swine fever virus (CSFV-ab ELISA kit, MEDIAN DIAGNOSTICS) whether a specific antibody against the administered antigen was generated and maintained. For the twice-administered group, blood collection was started 1 week after the time when the second administration was completed. Experiments were carried out using five mice per group, and the results thereof are illustrated in Table 1 and FIGS. 9 and 10. In Table 1, the S/P value was determined as positive in the case of a value of 0.14 or more and as negative in the case of a value of less than 0.14.

(50) TABLE-US-00001 TABLE 1 S/P value Ag 1 w 2 w 3 w 4 w 5 w 6 w 7 w Fn. E2:CBD Mouse 1 0.10 0.33 0.69 1.04 1.58 1.42 1.62 1.26 Mouse 2 0.01 0.32 0.82 0.87 0.84 0.89 0.63 0.72 Mouse 3 0.07 0.90 0.89 0.80 0.85 1.21 1.41 1.47 Mouse 4 0.04 0.21 0.31 0.25 0.30 0.35 0.43 1.15 Mouse 5 0.07 0.14 0.31 0.46 0.74 0.96 1.08 0.96 E2:pFc2 Mouse 1 0.44 1.30 2.18 2.27 2.19 2.07 1.91 2.09 Mouse 2 1.15 1.75 2.65 3.14 3.23 2.82 2.87 2.80 Mouse 3 0.06 0.57 1.25 1.40 1.17 1.08 1.11 1.06 Mouse 4 0.40 1.72 2.66 2.59 2.58 2.55 2.49 3.10 Mouse 5 0.44 1.54 3.00 2.55 2.66 2.71 2.43 2.95

(51) As illustrated in FIG. 9, it was confirmed that in the case of administering the antigens once, the pFc2-fused E2 recombinant antigen exhibited high reactivity from 1 week after administration and maintained the high activity more than 8 weeks. In contrast, it was confirmed that although the CBD-fused E2 recombinant antigen exhibited positive values, the reactivity thereof was low compared to the pFc2-fused E2 recombinant antigen.

(52) As shown in FIG. 10 and Table 1, it was confirmed that, in the case of administering the antigens twice, the CBD-fused E2 recombinant antigen also exhibited increased reactivity as compared to administering once, but still had low reactivity as compared to the pFc2-fused E2 recombinant antigen.

(53) In addition, serum samples of the same mice were sent to the Animal and Plant Quarantine Agency to identify the virus neutralization ability thereof. The results thereof are shown in Table 2 below.

(54) TABLE-US-00002 TABLE 2 Neutralizing antibody Experiment No. Antigen Individual No. value 2-1.sup.st (injected E2:CBD 1 64 twice) 2 32 3 32 4 32 5 128 E2:pFc2 1 128 2 256 3 32 4 256 5 512 2-2.sup.nd (injected E2:CBD 1 4 once) 2 4 3 <4 4 <4 5 <4 E2:pFc2 1 256 2 256 3 64 4 128 5 64 Negative <4 Positive 2048

(55) As illustrated in Table 2, it was confirmed that while the CBD-fused E2 recombinant antigen exhibited negative values in some mice when the antigen was administered once, the pFc2-fused E2 recombinant antigen exhibited a high potency of virus neutralization ability when administered both once and twice.

(56) 5.3. Virus Neutralization Ability Confirmation Experiment for pFc2-Fused E2 Recombinant Antigen

(57) To confirm whether the pFc2-fused E2 recombinant antigen also exhibits a high potency of virus neutralization ability in piglets, 4 swine fever antibody-negative piglets were selected and administered the pFc-fused E2 recombinant antigen twice, and serums obtained at intervals of 2 weeks were sent to the Animal and Plant Quarantine Agency to identify virus neutralization ability thereof. The results thereof are shown in Table 3 below.

(58) TABLE-US-00003 TABLE 3 Period 0 week (1.sup.st 2 weeks (2.sup.nd inoculation) inoculation) 4 weeks 6 weeks 8 weeks 10 weeks 12 weeks Neutralizing Neutralizing Neutralizing Neutralizing Neutralizing Neutralizing Neutralizing Individual antibody antibody antibody antibody antibody antibody antibody E2: #7 1 <1 8 7 7 7 6 pFc2 #8 <1 1 9 8 7 8 6 #9 <4 4 8 7 6 5 5 #10 2 4 10 9 7 7 6 Average 1.5 2.25 8.75 7.75 6.75 6.75 5.75

(59) As shown in Table 3, it was confirmed that all piglets exhibited positive values as in the experiments performed using the mice of Example 3.2.

(60) From the above results, it was confirmed that by fusing the pFc2 fragment of the present invention with various peptides or proteins for vaccines, not only the productivity but also solubility and stability of a target antigen were increased, inhibiting the agglomeration of the target antigen, and thus the recombinant antigen is effective in maintaining physiological activity or pharmacological activity thereof. It was also confirmed that by preparing a recombinant antigen by fusing an antigen with a pFc2 fragment, the pFc2 fragment exhibited a self-adjuvanting effect and a self-adjuvant effect, and thus not only the immunogenicity but also productivity and stability of a target antigen could be significantly increased.

(61) The foregoing description of the present invention is provided for illustrative purposes only, and it will be understood by those of ordinary skill in the art to which the present invention pertains that the present invention may be easily modified into other particular forms without changing the technical spirit or essential characteristics of the present invention. Thus, the above-described embodiments should be construed as being provided for illustrative purposes only and not for purposes of limitation.

INDUSTRIAL APPLICABILITY

(62) The present invention relates to an antigen fused with a porcine Fc fragment, and more particularly, to a vaccine composition having a self-adjuvanting effect by binding an Fc fragment to various antigens, and a preparation method thereof. Since the antigens fused with an Fc fragment of the present invention have a self-adjuvanting effect, they can markedly increase the preventive and/or treatment effects of the vaccine composition, so it is expected to be widely usable by applying to various vaccine compositions.